Motexafin Gadolinium Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Phase 1 Completed Jonsson Comprehensive Cancer Center National Cancer Institute (NCI) · collab

Treatment

Summary

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Motexafin gadolinium may increase the effectiveness of radiation therapy by making tumor cells more sensitive to radiation. PURPOSE: Phase I trial to study the effectiveness of motexafin gadolinium plus radiation therapy in treating patients who have newly diagnosed glioblastoma multiforme.

Timeline

Start: 1998-07
Primary completion: —
Completion: —

Publications

Results Ford JM, Seiferheld W, Alger JR, Wu G, Endicott TJ, Mehta M, Curran W, Phan SC. Results of the phase I dose-escalating study of motexafin gadolinium with standard radiotherapy in patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2007 Nov 1;69(3):831-8. doi: 10.1016/j.ijrobp.2007.04.017. Epub 2007 Jun 8.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	motexafin gadolinium	Diagnostic / imaging agent	4 mg/kg	Intravenous
Subject	motexafin gadolinium	Diagnostic / imaging agent	5 mg/kg	Intravenous
Subject	motexafin gadolinium	Diagnostic / imaging agent	5.3 mg/kg	Intravenous

Motexafin Gadolinium Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Summary

Timeline

Publications

Drugs

Indications